Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.78 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.68 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.66 |
| ▸ | AHCY | P23526 | 2/20 | 0.61 |
| ▸ | NADK | O95544 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.58 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118571 | 1.00 | ADORA3 (0.78) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL15926825 | 1.00 | ADORA3 (0.78) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL19849513 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL5354361 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL5354351 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL13860338 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL5354088 | 0.88 | ADORA3 (1.00) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL13860337 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL5354093 | 0.88 | ADORA3 (1.00) | ADORA3DNMT1DNMT3BADORA2AAHCY | |
| SCHEMBL5362972 | 0.88 | ADORA3 (0.77) | ADORA3DNMT1DNMT3BADORA2AAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| EP-2364086-B1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-8575127-B2 | Antithrombotic diadenosine tetraphosphates and related analogs | GLSYNTHESIS INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2364086-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | Glsynthesis Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010059215-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GLSYNTHESIS INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257252-A1 | NOVEL ANTITHROMBOTIC DIADENOSINE TETRAPHOSPHATES AND RELATED ANALOGS | GP6, P2RY6, PFKP | ADORA3 59/4885DNMT1 2221/4885DNMT3B 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.